Gracell Biotechnologies (GRCL)
NASDAQ:GRCL
US Market
Holding GRCL?
Track your performance easily

Gracell Biotechnologies (GRCL) Financial Statements

134 Followers

Gracell Biotechnologies Financial Overview

Gracell Biotechnologies's market cap is currently ―. The company's EPS TTM is $-1.017; its P/E ratio is -10.08; Gracell Biotechnologies is scheduled to report earnings on March 11, 2024, and the estimated EPS forecast is $-0.04. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue-$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit-----
EBIT-$ -170.06M$ -144.65M$ -157.16M$ -127.26M
EBITDA-$ -170.06M$ -144.65M$ -157.16M$ -127.26M
Net Income Common Stockholders-$ -171.93M$ -146.31M$ -158.58M$ -128.59M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 211.42M$ 1.63B$ 1.71B$ 1.69B$ 1.83B
Total Assets$ 240.14M$ 1.84B$ 1.90B$ 1.93B$ 2.06B
Total Debt$ 26.53M$ 203.78M$ 182.07M$ 170.89M$ 155.18M
Net Debt$ -184.89M$ -1.43B$ -1.53B$ -1.52B$ -1.68B
Total Liabilities$ 40.67M$ 311.43M$ 285.38M$ 260.72M$ 232.77M
Stockholders Equity$ 1.38B$ 1.53B$ 1.61B$ 1.67B$ 1.83B
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in USD

Gracell Biotechnologies Earnings and Revenue History

Gracell Biotechnologies Debt to Assets

Gracell Biotechnologies Cash Flow

Gracell Biotechnologies Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis